AstraZeneca updates Covid-19 vaccine efficacy rate to 76%

(Reuters) - AstraZeneca said its COVID-19 vaccine was 76% effective at preventing symptomatic illness in a new analysis of its major U.S. trial, slightly lower than the level announced this week in a report criticised for using outdated information.

U.S. health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday showing the vaccine was 79% effective. Here are comments on the latest developments: MENE PANGALOS, EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS.....

This article is no longer available in our repository.

There could be multiple reasons for this.